All Stories

  1. Advanced glycomics approach for characterization of IgG glycan alterations and immune modulation in traumatic brain injury
  2. Peer Review of “Material-Driven Therapeutics to Establish a Penetrating Traumatic Brain Injury Rat Model and Implantation of a 3D-Printed Scaffold: Pre-Experimental Pilot Study”
  3. A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials
  4. Beyond immune privilege: the brain as a dynamic immunological interface
  5. Serum biomarker trajectory clusters predict functional outcome and quality of life for traumatic brain injury
  6. Multifunctional Nanoparticles in Traumatic Brain Injury: From Targeted Imaging and Diagnosis to Innovative Therapeutics
  7. Potential Role of Serum Cytokines and Chemokines as Biomarkers of Injury Severity and Functional Outcomes Following Pediatric Traumatic Brain Injury
  8. Insomnia and Mental Health Outcomes After Catastrophic Disasters: A Cross-Sectional Study Examining the Long-Term Effects of the Beirut Port Explosion
  9. Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling
  10. Alteration of Metabolic Profile in Patients with Narcolepsy Type 1
  11. Exploring the Anti-Leukemic Effect of the Synthetic Retinoid ST1926 on Malignant T Cells: A Comprehensive Proteomics Approach
  12. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities
  13. Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury
  14. The impact of posttraumatic stress disorder and head injury on reactive and appetitive aggression in adult Syrian refugees in Lebanon.
  15. Emerging understandings of the role of exosomes in atherosclerosis
  16. Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification
  17. Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics
  18. Vitamin D Deficiency Does Not Affect Cognition and Neurogenesis in Adult C57Bl/6 Mice
  19. Western diet induces mild metabolic impairment and aggravates neuropathology in an experimental mouse model of traumatic brain injury
  20. 1,25-Dihydroxyvitamin D3 Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line
  21. Cultural assimilation of adult Syrian refugees in Lebanon: Effect modification by religiosity and sex on the relation between cultural adversities and common mental health disorders.
  22. MicroRNAs as biomarkers of brain injury in neonatal encephalopathy: an observational cohort study
  23. Functional Selection of Tau Oligomerization‐Inhibiting Aptamers
  24. Functional Selection of Tau Oligomerization‐Inhibiting Aptamers
  25. Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development
  26. Transcriptomic Signatures of Neuronally Derived Extracellular Vesicles Reveal the Presence of Olfactory Receptors in Clinical Samples from Traumatic Brain Injury Patients
  27. Determination of Medicago orbicularis Antioxidant, Antihemolytic, and Anti-Cancerous Activities and Its Augmentation of Cisplatin-Induced Cytotoxicity in A549 Lung Cancer Cells
  28. The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury
  29. The Use of Biofluid Markers to Evaluate the Consequences of Sport-Related Subconcussive Head Impact Exposure: A Scoping Review
  30. Estrogen Receptor and the Gender Bias in Raynaud’s Phenomenon
  31. Traumatic Brain Injury and Opioids: Twin Plagues of the Twenty-First Century
  32. Biomaterials in Traumatic Brain Injury: Perspectives and Challenges
  33. Functional connectivity, tissue microstructure and T2 at 11.1 Tesla distinguishes neuroadaptive differences in two traumatic brain injury models in rats: A Translational Outcomes Project in NeuroTrauma (TOP-NT) UG3 phase study
  34. Translating from mice to humans: using preclinical blood-based biomarkers for the prognosis and treatment of traumatic brain injury
  35. Sleep Disruption in a Mouse Model of Chronic Traumatic Brain Injury
  36. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
  37. Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
  38. LC-MS/MS Quantitation of HILIC-Enriched N-glycopeptides Derived from Low-Abundance Serum Glycoproteins in Patients with Narcolepsy Type 1
  39. Biomaterials in Traumatic Brain Injury: Challenges and Perspectives
  40. <em>Medicago orbicularis</em> Has Antioxidant, Antihemolytic, and Anti-cancerous Activities and Augments Cisplatin-Induced Cytotoxicity in A549 Lung Cancer Cells
  41. The Antitumor Effect of the DNA Polymerase Alpha Inhibitor ST1926 in Glioblastoma: A Proteomics Approach
  42. Biomaterials in Traumatic Brain Injury: Challenges and Perspectives
  43. Traumatic Brain Injury in Cameroon: A Prospective Observational Study in a Level I Trauma Centre
  44. Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
  45. Serum Biomarker Concentrations upon Admission in Acute Traumatic Brain Injury: Associations with TBI Severity, Toxoplasma gondii Infection, and Outcome in a Referral Hospital Setting in Cameroon
  46. Serum Biomarker Concentrations on Admission in Acute Traumatic Brain Injury: Associations with, TBI Severity, <em>Toxoplasma gondii </em>Infection and Outcome in a Referral Hospital Setting, Cameroon
  47. Association between Cerebrospinal Fluid and Serum Biomarker Levels and Diagnosis, Injury Severity, and Short-Term Outcomes in Patients with Acute Traumatic Spinal Cord Injury
  48. Inflammation and hypertension: Underlying mechanisms and emerging understandings
  49. LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1
  50. Posttraumatic stress disorder among the Lebanese population and Syrian refugees: A systematic review.
  51. Receptor tyrosine kinases in major depressive disorder
  52. Concomitant Guillain–Barré Syndrome and COVID-19: A Meta-Analysis of Cases
  53. Characterization of Calpain and Caspase-6-Generated Glial Fibrillary Acidic Protein Breakdown Products Following Traumatic Brain Injury and Astroglial Cell Injury
  54. Neurological Outcomes Following Mitoquinone Supplementation in Mice, 3 and 7 Days Post Repeated Mild Traumatic Brain Injury
  55. Characterization of Calpain and Caspase-6 Generated Glial Fibrillary Acidic Protein Breakdown Products Following Traumatic Brain Injury and Astroglial Cell Injury
  56. Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation
  57. Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
  58. The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model
  59. Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers
  60. Gasoline fume inhalation induces apoptosis, inflammation, and favors Th2 polarization in C57BL/6 mice
  61. Mitoquinone Helps Combat the Neurological, Cognitive, and Molecular Consequences of Open Head Traumatic Brain Injury at Chronic Time Point
  62. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients
  63. On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape
  64. Exploring the evidence for the effectiveness of health interventions for COVID-19 targeting migrants: a systematic review protocol
  65. Blood-based traumatic brain injury biomarkers – Clinical utilities and regulatory pathways in the United States, Europe and Canada
  66. Modulation of Neuro-Inflammatory Signals in Microglia by Plasma Prekallikrein and Neuronal Cell Debris
  67. Correction to: Elevation of Pro‑inflammatory and Anti‑inflammatory Cytokines in Rat Serum after Acute Methamphetamine Treatment and Traumatic Brain Injury
  68. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy
  69. Elevation of Pro-inflammatory and Anti-inflammatory Cytokines in Rat Serum after Acute Methamphetamine Treatment and Traumatic Brain Injury
  70. Microvascular imaging ultrasound (MicroV) and power Doppler vascularization analysis in a pediatric population with early scrotal pain onset
  71. Long-term cognitive deficits after traumatic brain injury associated with microglia activation
  72. Sweat metabolome and proteome: Recent trends in analytical advances and potential biological functions
  73. Neurotrauma investigation through spatial omics guided by mass spectrometry imaging: Target identification and clinical applications
  74. Bioinformatics Analysis of Allele Frequencies and Expression Patterns of ACE2, TMPRSS2 and FURIN in Different Populations and Susceptibility to SARS-CoV-2
  75. National Trauma and Substance Use Disorders: A Slippery Slope in Lebanon
  76. Meningioma genomics: a therapeutic challenge for clinicians
  77. Inflammatory Basis of Atherosclerosis: Modulation by Sex Hormones
  78. MS‐based glycomics and glycoproteomics methods enabling isomeric characterization
  79. Potentiating Hemorrhage in a Periadolescent Rat Model of Closed-Head Traumatic Brain Injury Worsens Hyperexcitability but Not Behavioral Deficits
  80. Beirut Ammonium Nitrate Blast: Analysis, Review, and Recommendations
  81. In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer
  82. Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis
  83. Corrigendum
  84. SARS-CoV-2 and Stroke Characteristics
  85. Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment
  86. Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
  87. Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology
  88. A Bioinformatics Systems Biology Analysis of the Current Oral Proteomic Biomarkers and Implications for Diagnosis and Treatment of External Root Resorption
  89. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
  90. Analysis of the Neuroproteome Associated With Cell Therapy After Intranigral Grafting in a Mouse Model of Parkinson Disease
  91. Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases
  92. Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap
  93. Psychological distress experienced by physicians and nurses at a tertiary care center in Lebanon during the COVID-19 outbreak
  94. Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I:C)-stimulated macrophages
  95. Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms
  96. Acute ischemic stroke biomarkers: a new era with diagnostic promise?
  97. Thorough overview of ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury
  98. C-Reactive Protein for Prediction or Early Detection of Pre-Eclampsia: A Systematic Review
  99. Characterization of Traumatic Brain Injury Research in the Middle East and North Africa Region: A Systematic Review
  100. Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication Severity
  101. Depression following traumatic brain injury: a comprehensive overview
  102. Vascular Cells Proteome Associated with Bradykinin and Leptin Inflammation and Oxidative Stress Signals
  103. Advances in Cardiovascular Biomarker Discovery
  104. Secretome Analysis of Inductive Signals for BM-MSC Transdifferentiation into Salivary Gland Progenitors
  105. Characteristics and Impact of U.S. Military Blast-Related Mild Traumatic Brain Injury: A Systematic Review
  106. <p>Telepsychiatry in the Arab World: A Viewpoint Before and During COVID-19</p>
  107. Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury
  108. Preneoplastic lesions fimbria pan-proteomic studies establish the fimbriectomy benefit for BRCA1/2 patients and identify early diagnosis markers of HGSC
  109. On-tissue spatially-resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape
  110. Epigenetic Studies Revealed a Ghost Proteome in PC1/3 KD Macrophages under Antitumoral Resistance Induced by IL-10
  111. Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone
  112. Effects of the Oncoprotein PAX3-FOXO1 on Modulation of Exosomes Function and Protein Content: Implications on Oxidative Stress Protection and Enhanced Plasticity
  113. The Role of Epac in Cancer Progression
  114. Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study
  115. Protein Expression Analysis of an In Vitro Murine Model of Prostate Cancer Progression: Towards Identification of High-Potential Therapeutic Targets
  116. Novel therapeutic strategies for spinal osteosarcomas
  117. <p>Prevalence of Eating Disorders Among Medical Students in a Lebanese Medical School: A Cross-Sectional Study</p>
  118. Dysfunctional cerebrovascular tone contributes to cognitive impairment in a non-obese rat model of prediabetic challenge: Role of suppression of autophagy and modulation by anti-diabetic drugs
  119. Spinal sarcomas and immunity: An undervalued relationship
  120. Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization
  121. EPAC in Vascular Smooth Muscle Cells
  122. The Mitochondria: A Target of Polyphenols in the Treatment of Diabetic Cardiomyopathy
  123. Modulation of proteomic and inflammatory signals by Bradykinin in podocytes
  124. Western diet aggravates neuronal insult in post-traumatic brain injury: Proposed pathways for interplay
  125. Serum Glycomics Profiling of Patients with Primary Restless Legs Syndrome Using LC–MS/MS
  126. The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth
  127. Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets
  128. Circulating Brain Injury Exosomal Proteins following Moderate-to-Severe Traumatic Brain Injury: Temporal Profile, Outcome Prediction and Therapy Implications
  129. Traumatic brain injury and methamphetamine: A double-hit neurological insult
  130. Editorial: Biomarkers in Neurology
  131. Gender‐biased kidney damage in mice following exposure to tobacco cigarette smoke: More protection in premenopausal females
  132. Location of neonatal microglia drives small extracellular vesicles content and biological functions in vitro
  133. P.867 Assessing cognitive behavioral therapy for insomnia in individuals with cannabis use disorder utilizing actigraphy and serum biomarkers
  134. Transcriptomic profiling of trophoblast fusion using BeWo and JEG-3 cell lines
  135. PC1/3 KD Macrophages Exhibit Resistance to the Inhibitory Effect of IL-10 and a Higher TLR4 Activation Rate, Leading to an Anti-Tumoral Phenotype
  136. Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges
  137. Proteomic Profiling of Rhabdomyosarcoma-Derived Exosomes Yield Insights into Their Functional Role in Paracrine Signaling
  138. Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging of Lipids in Experimental Model of Traumatic Brain Injury Detecting Acylcarnitines as Injury Related Markers
  139. Mapping Spatiotemporal Microproteomics Landscape in Experimental Model of Traumatic Brain Injury Unveils a link to Parkinson's Disease*
  140. Tobacco cigarette smoking exacerbates aortic calcification in an early stage of myocardial infarction in a female mouse model
  141. Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase
  142. Enhanced setup for wired continuous long-term EEG monitoring in juvenile and adult rats: application for epilepsy and other disorders
  143. Lestaurtinib (CEP-701) modulates the effects of early life hypoxic seizures on cognitive and emotional behaviors in immature rats
  144. Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury
  145. Functional pathways associated with human carotid atheroma: a proteomics analysis
  146. Hydrogels for Advanced Stem Cell Therapies: A Biomimetic Materials Approach for Enhancing Natural Tissue Function
  147. Psychiatric Disorders
  148. Qualitative vs. Quantitative Methods in Psychiatric Research: Updated
  149. Rodent Models of Methamphetamine Misuse: Mechanisms of Methamphetamine Action and Comparison of Different Rodent Paradigms
  150. A shared comparison of diabetes mellitus and neurodegenerative disorders
  151. Novel biomarker signatures for idiopathic REM sleep behavior disorder
  152. Transplantation of Embryonic Neural Stem Cells and Differentiated Cells in a Controlled Cortical Impact (CCI) Model of Adult Mouse Somatosensory Cortex
  153. Delayed sleep phase syndrome and bipolar disorder: Pathogenesis and available common biomarkers
  154. LC-MS/MS glycomics of idiopathic rapid eye movement sleep behavior disorder
  155. Lipid Changes Associated with Traumatic Brain Injury Revealed by 3D MALDI-MSI
  156. Temporally and spatially-resolved microproteomics and MALDI MSI lipidomic analysis for traumatic brain injury biomarker identification
  157. SLC35B4, an Inhibitor of Gluconeogenesis, Responds to Glucose Stimulation and Downregulates Hsp60 among Other Proteins in HepG2 Liver Cell Lines
  158. Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms
  159. Extracellular vesicles: pathogenetic, diagnostic and therapeutic value in traumatic brain injury
  160. Insomnia in hospitalized psychiatric patients: prevalence and associated factors
  161. Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial
  162. Paclitaxel treatment and PC1/3 knockdown in macrophages is a promising anti-glioma strategy as revealed by proteomics and cytotoxicity studies
  163. Docosahexaenoic acid (DHA) enhances the therapeutic potential of neonatal neural stem cell transplantation post—Traumatic brain injury
  164. Correction to: Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury
  165. Coupling Large-Scale Omics Data for Deciphering Systems Complexity
  166. Genomic alterations during p53-dependent apoptosis induced by γ-irradiation of Molt-4 leukemia cells
  167. Characterization and assessment of potential microRNAs involved in phosphate-induced aortic calcification
  168. Spatially-Resolved Top-down Proteomics Bridged to MALDI MS Imaging Reveals the Molecular Physiome of Brain Regions
  169. Proteome profiling in the aorta and kidney of type 1 diabetic rats
  170. Glycosylation Changes in Brain Cancer
  171. The diagnostic values of UCH-L1 in traumatic brain injury: A meta-analysis
  172. Traumatic brain injury, diabetic neuropathy and altered-psychiatric health: The fateful triangle
  173. Erratum to: Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions
  174. Preclinical modelling of militarily relevant traumatic brain injuries: Challenges and recommendations for future directions
  175. Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer
  176. RhoA Inhibitor Treatment At Acute Phase of Spinal Cord Injury May Induce Neurite Outgrowth and Synaptogenesis
  177. Multitargeted Flavonoid Inhibition of the Pathogenic Bacterium Staphylococcus aureus: A Proteomic Characterization
  178. Thyroxine (T4) Transfer from Blood to Cerebrospinal Fluid in Sheep Isolated Perfused Choroid Plexus: Role of Multidrug Resistance-Associated Proteins and Organic Anion Transporting Polypeptides
  179. Risk of obstructive sleep apnea and excessive daytime sleepiness in hospitalized psychiatric patients
  180. The Application of Proteomics to Traumatic Brain and Spinal Cord Injuries
  181. Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients
  182. Novel Bioinformatics–Based Approach for Proteomic Biomarkers Prediction of Calpain-2 & Caspase-3 Protease Fragmentation: Application to βII-Spectrin Protein
  183. Glycoproteins Enrichment and LC-MS/MS Glycoproteomics in Central Nervous System Applications
  184. Acute Exposure to Cigarette Smoking Followed by Myocardial Infarction Aggravates Renal Damage in an In Vivo Mouse Model
  185. Functional, Cellular, and Molecular Remodeling of the Heart under Influence of Oxidative Cigarette Tobacco Smoke
  186. AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study
  187. Biofluid Proteomics and Biomarkers in Traumatic Brain Injury
  188. Degradomics in Neurotrauma: Profiling Traumatic Brain Injury
  189. Effect of Second-Hand Tobacco Smoke on the Nitration of Brain Proteins: A Systems Biology and Bioinformatics Approach
  190. Efficient and Accurate Algorithm for Cleaved Fragments Prediction (CFPA) in Protein Sequences Dataset Based on Consensus and Its Variants: A Novel Degradomics Prediction Application
  191. Neuroproteomics Studies: Challenges and Updates
  192. The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma
  193. Neuroproteomics and Systems Biology Approach to Identify Temporal Biomarker Changes Post Experimental Traumatic Brain Injury in Rats
  194. Cigarette Smoking-Induced Cardiac Hypertrophy, Vascular Inflammation and Injury Are Attenuated by Antioxidant Supplementation in an Animal Model
  195. Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification
  196. Epidemiology and clinical characteristics of traumatic brain injury in Lebanon
  197. Deciphering the Role of Emx1 in Neurogenesis: A Neuroproteomics Approach
  198. Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
  199. Restless leg syndrome in hospitalized psychiatric patients in Lebanon: a pilot study
  200. The kinetics of angiotensin-I metabolism in human carotid atheroma: An emerging role for angiotensin (1–7)
  201. Proteomic Analysis of the Spatio-temporal Based Molecular Kinetics of Acute Spinal Cord Injury Identifies a Time- and Segment-specific Window for Effective Tissue Repair
  202. Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury
  203. Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study
  204. The Effect of Chronic Methamphetamine Exposure on the Hippocampal and Olfactory Bulb Neuroproteomes of Rats
  205. Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma
  206. Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients
  207. Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment
  208. Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines
  209. Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia
  210. RYR2, PTDSS1 and AREG genes are implicated in a Lebanese population-based study of copy number variation in autism
  211. Application of Systems Biology to Neuroproteomics: The Path to Enhanced Theranostics in Traumatic Brain Injury
  212. Postnatal Neural Stem Cells in Treating Traumatic Brain Injury
  213. Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application
  214. Metformin and Ara-a Effectively Suppress Brain Cancer by Targeting Cancer Stem/Progenitor Cells
  215. Mechanical stretch-induced vascular hypertrophy occurs through modulation of leptin synthesis-mediated ROS formation and GATA-4 nuclear translocation
  216. Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to Cancer Immunotherapy: A Proteomic Study
  217. Culture of PC12 neuronal cells in GelMA hydrogel for brain tissue engineering
  218. Correction: Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment
  219. Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment
  220. Cleaved Fragments Prediction Algorithm (CFPA) application to calpain and caspase in apoptosis and necrotic cell death
  221. Proteomics studies in inner ear disorders: pathophysiology and biomarkers
  222. Biomarker Identification in Psychiatric Disorders
  223. Autoantibodies in traumatic brain injury and central nervous system trauma
  224. Nanotheragnostic Applications for Ischemic and Hemorrhagic Strokes: Improved Delivery for a Better Prognosis
  225. Neuro-proteomics and Neuro-systems Biology in the Quest of TBI Biomarker Discovery
  226. Protein Biomarkers in Traumatic Brain Injury: An Omics Approach
  227. CSF and Plasma Amyloid-β Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury
  228. Minor and Repetitive Head Injury
  229. Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions
  230. Recent updates on drug abuse analyzed by neuroproteomics studies: Cocaine, Methamphetamine and MDMA
  231. Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products
  232. A neuroproteomic and systems biology analysis of rat brain post intracerebral hemorrhagic stroke
  233. Post-Genomics Nanotechnology Is Gaining Momentum: Nanoproteomics and Applications in Life Sciences
  234. Stem cells in neuroinjury and neurodegenerative disorders: challenges and future neurotherapeutic prospects
  235. Bioinformatics Approach to Understanding Interacting Pathways in Neuropsychiatric Disorders
  236. Uses and challenges of bioinformatic tools in mass spectrometric-based proteomic brain perturbation studies
  237. Different expression of ubiquitin C-terminal hydrolase-L1 and αII-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis
  238. Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study
  239. CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat
  240. Biomarkers Track Damage after Graded Injury Severity in a Rat Model of Penetrating Brain Injury
  241. The Challenge of Mild Traumatic Brain Injury: Role of Biochemical Markers in Diagnosis of Brain Damage
  242. An updated overview of animal models in neuropsychiatry
  243. Overpressure blast-wave induced brain injury elevates oxidative stress in the hypothalamus and catecholamine biosynthesis in the rat adrenal medulla
  244. Biomarkers in psychiatry: how close are we?
  245. Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury
  246. Pilot Study Using Proteomics to Identify Predictive Biomarkers of Necrotizing Enterocolitis from Buccal Swabs in Very Low Birth Weight Infants
  247. Editorial
  248. In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system
  249. Microbial cell components induced tolerance to flagellin-stimulated inflammation through Toll-like receptor pathways in intestinal epithelial cells
  250. Proteomic analysis and brain-specific systems biology in a rodent model of penetrating ballistic-like brain injury
  251. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma
  252. Identification of Proteins Sensitive to Thermal Stress in Human Neuroblastoma and Glioma Cell Lines
  253. Global Renal Gene Expression Profiling Analysis in B2-Kinin Receptor Null Mice: Impact of Diabetes
  254. Anesthetic Management in Body Countouring Surgery
  255. Systems Biology, Bioinformatics, and Biomarkers in Neuropsychiatry
  256. Methods in Drug Abuse Models: Comparison of Different Models of Methamphetamine Paradigms
  257. Methods in Tobacco Abuse: Proteomic Changes Following Second-Hand Smoke Exposure
  258. Qualitative Versus Quantitative Methods in Psychiatric Research
  259. Animal Models of Self-Injurious Behaviour: An Overview
  260. Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside
  261. Identification of tyrosine nitration in UCH-L1 and GAPDH
  262. Leveraging Biomarker Platforms and Systems Biology for Rehabilomics and Biologics Effectiveness Research
  263. Engineered Multifunctional Nanotools for Biological Applications
  264. Resolving the Negative Data Publication Dilemma in Translational Stroke Research
  265. Dual Vulnerability of Tau to Calpains and Caspase-3 Proteolysis Under Neurotoxic and Neurodegenerative Conditions
  266. Pharmacological Therapeutics for Detoxification in Addictive Disorders
  267. Food Addiction and Obesity: Evidence from Bench to Bedside
  268. Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats
  269. Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype
  270. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats
  271. Methods in Systems Biology of Experimental Methamphetamine Drug Abuse
  272. Systems Biology and Theranostic Approach to Drug Discovery and Development to Treat Traumatic Brain Injury
  273. Methamphetamine- and Trauma-Induced Brain Injuries: Comparative Cellular and Molecular Neurobiological Substrates
  274. Gliotypic Neural Stem Cells Transiently Adopt Tumorigenic Properties During Normal Differentiation
  275. Calmodulin-Binding Proteome in the Brain
  276. Methods in Drug Abuse Neuroproteomics: Methamphetamine Psychoproteome
  277. Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation
  278. Psychoproteomic Analysis of Rat Cortex Following Acute Methamphetamine Exposure
  279. Psychiatric research: psychoproteomics, degradomics and systems biology
  280. Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats
  281. Speed, Cocaine, and Other Psychostimulants Death Rates
  282. Performance Enhancing, Non-Prescription Use of Ritalin
  283. Calpain and caspase proteolytic markers co-localize with rat cortical neurons after exposure to methamphetamine and MDMA
  284. Calpain-Mediated Collapsin Response Mediator Protein-1, -2, And -4 Proteolysis after Neurotoxic And Traumatic Brain Injury
  285. Application of the data mining techniques to the systems biology of neuritogenesis
  286. Novel neuroproteomic approaches to studying traumatic brain injury
  287. Ecstasy Toxicity
  288. Performance Enhancement and Adverse Consequences of MDMA
  289. Calpain- and caspase-mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure
  290. Novel Differential Neuroproteomics Analysis of Traumatic Brain Injury in Rats
  291. Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells
  292. Neuroproteomics in neurotrauma
  293. Concurrent calpain and caspase-3 mediated proteolysis of αII-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury
  294. A Multidimensional Differential Proteomic Platform Using Dual-Phase Ion-Exchange Chromatography−Polyacrylamide Gel Electrophoresis/Reversed-Phase Liquid Chromatography Tandem Mass Spectrometry
  295. Rapid Discovery of Putative Protein Biomarkers of Traumatic Brain Injury by SDS–PAGE–Capillary Liquid Chromatography–Tandem Mass Spectrometry
  296. Proteomics Studies of Traumatic Brain Injury
  297. SOME IMMUNOLOGICAL ASPECTS OF PATIENTS WITH RHINITIS IN LEBANON
  298. Major histocompatibility complex class I and II antigens frequencies in selected groups of Lebanese